Literature DB >> 19252524

miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.

E J Noonan1, R F Place, D Pookot, S Basak, J M Whitson, H Hirata, C Giardina, R Dahiya.   

Abstract

Histone deacetylases (HDACs) are frequently overexpressed in broad range of cancer types, where they alter cellular epigenetic programming to promote cell proliferation and survival. However, the mechanism by which HDACs become overexpressed in human cancers remains somewhat of a mystery. In this study, we investigated the expression and functional significance of miR-449a in prostate cancer cells. Using real-time PCR, we found that miR-449a is downregulated in prostate cancer tissues relative to patient-matched control tissue. Introduction of miR-449a into PC-3 prostate cancer cells resulted in cell-cycle arrest, apoptosis and a senescent-like phenotype. In silico analysis of 3'-UTR regions identified a number of genes involved in cell-cycle regulation as putative targets of miR-449a. Using a luciferase 3'-UTR reporter system, we established that HDAC-1 (histone deacetylase 1), a gene that is frequently overexpressed in many types of cancer, is a direct target of miR-449a. Further, our data indicate that miR-449a regulates cell growth and viability in part by repressing the expression of HDAC-1 in prostate cancer cells. Our findings provide new insight into the function of miRNA in regulating HDAC expression in normal versus cancerous tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252524     DOI: 10.1038/onc.2009.19

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  166 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  miR-484 regulates mitochondrial network through targeting Fis1.

Authors:  Kun Wang; Bo Long; Jian-Qin Jiao; Jian-Xun Wang; Jin-Ping Liu; Qian Li; Pei-Feng Li
Journal:  Nat Commun       Date:  2012-04-17       Impact factor: 14.919

Review 3.  Epigenetic mechanisms in inflammation.

Authors:  D Bayarsaihan
Journal:  J Dent Res       Date:  2011-01       Impact factor: 6.116

Review 4.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

Review 5.  Cross talk between microRNA and coding cancer genes.

Authors:  Tanja Kunej; Irena Godnic; Simon Horvat; Minja Zorc; George A Calin
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

6.  HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.

Authors:  Ludivine Renaud; Lillianne G Harris; Santhosh K Mani; Harinath Kasiganesan; James C Chou; Catalin F Baicu; An Van Laer; Adam W Akerman; Robert E Stroud; Jeffrey A Jones; Michael R Zile; Donald R Menick
Journal:  Circ Heart Fail       Date:  2015-09-14       Impact factor: 8.790

Review 7.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

8.  MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Authors:  Luciano Mazzoccoli; Marcela Cristina Robaina; Alexandre Gustavo Apa; Martin Bonamino; Luciana Wernersbach Pinto; Eduardo Queiroga; Carlos E Bacchi; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-09       Impact factor: 4.553

Review 9.  Potential function of miRNAs in herpetic stromal keratitis.

Authors:  Sachin Mulik; Siddheshvar Bhela; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

10.  microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.

Authors:  Zhenze Zhao; Xiuye Ma; Derek Sung; Monica Li; Adam Kosti; Gregory Lin; Yidong Chen; Alexander Pertsemlidis; Tzu-Hung Hsiao; Liqin Du
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.